** Shares of Moderna MRNA.O fall 3.28% to $32.48 premarket
** U.S. health officials are reevaluating a $590 million contract that was awarded to co for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources
** The review is part of a government push to examine spending on messenger RNA-based vaccines, the technology that powered Moderna's COVID vaccine, the report added
** The U.S. government awarded MRNA $590 million in January to advance the development of its bird flu vaccine
** Shares have fallen nearly 65% in the last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。